Epetraborole (R-mandelate)

• UNSPSC Description:

  Epetraborole R-mandelate is a novel leucyl-tRNA synthetase (LeuRS) inhibitor (IC50=0.31 μM), thereby inhibiting protein synthesis. Epetraborole R-mandelate can be used in multidrug-resistant gram-negative pathogens infection research[1][2][3].

• Target Antigen:

  Aminoacyl-tRNA Synthetase; Bacterial

• Type:

  Reference compound

• Related Pathways:

  Anti-infection;Metabolic Enzyme/Protease

• Field of Research:

  Infection

• Assay Protocol:

  https://www.medchemexpress.com/epetraborole-r-mandelate.html

• Smiles:

  OC([C@@H](C1=CC=CC=C1)O)=O.OCCCOC2=C3C([C@H](OB3O)CN)=CC=C2

• Molecular Weight:

  389.21

• References & Citations:

  [1]Goldstein EJ, et al. Comparative in vitro activities of GSK2251052, a novel boron-containing leucyl-tRNA synthetase inhibitor, against 916 anaerobic organisms. Antimicrob Agents Chemother. 2013 May;57(5):2401-4.|[2]O'Dwyer K, et al. Bacterial resistance to leucyl-tRNA synthetase inhibitor GSK2251052 develops during treatment of complicated urinary tract infections. Antimicrob Agents Chemother. 2015 Jan;59(1):289-98.|[3]Sutcliffe JA. Antibiotics in development targeting protein synthesis. Ann N Y Acad Sci. 2011 Dec;1241:122-52.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  Phase 3

• CAS Number:

  1234563-15-5